QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for MoxDuo IV Pain Therapy

 
 
 
 
Combination of Morphine plus Oxycodone IV Demonstrates Improved
Analgesia and Tolerability Compared to IV Morphine
SYDNEY and BEDMINSTER, N.J., Aug 9 /PRNewswire/ -- QRxPharma
Limited announced today positive results of its Phase...

...

More on Sciencestage.com